1. Home
  2. MTEK vs QNRX Comparison

MTEK vs QNRX Comparison

Compare MTEK & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.16

Market Cap

11.7M

Sector

N/A

ML Signal

HOLD

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$4.45

Market Cap

11.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
QNRX
Founded
2008
2018
Country
Israel
United States
Employees
14
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
11.6M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
MTEK
QNRX
Price
$1.16
$4.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
351.5K
29.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$4.11
52 Week High
$4.27
$41.80

Technical Indicators

Market Signals
Indicator
MTEK
QNRX
Relative Strength Index (RSI) 46.03 28.87
Support Level $1.08 N/A
Resistance Level $1.44 $6.84
Average True Range (ATR) 0.13 0.47
MACD 0.01 -0.05
Stochastic Oscillator 38.46 14.10

Price Performance

Historical Comparison
MTEK
QNRX

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: